Araceli Biosciences Adds Investor to $4.5 Million Round
Nov 12, 2026
Funding
Enveda Raises $311 Million for AI Drug Discovery
Sep 24, 2026
Enveda raised a $311 million Series E at a $2 billion valuation to advance drugs discovered from plants and microbes into clinical trials.
Enveda raised a $311 million Series E at a $2 billion valuation, according to TechCrunch. The valuation is twice the figure Enveda reached 12 months earlier.
Catalio Capital Management led the round, with participation from Iconiq Capital and other investors. Enveda uses AI and other methods to identify potential medicines from plants and microbes.
The company is testing several drug candidates in human clinical trials. These include a treatment for severe skin conditions and a drug intended to help patients maintain weight loss after they stop taking GLP-1 medicines.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Nov 12 Huang's exit puts extra pressure on Anthropic's IPO next week, investors tell Fortune Nov 12 Mirendil raises $1 billion Series A to make frontier AI research cheaper and faster Nov 12 Dallas AI startup 4Minds raises $15 million at a $500 million valuation Nov 12 Norwest raises $4 billion fund, its largest, to invest more in AI startups Nov 12 Mount Thor raises $45 million to rent Apple Macs in the cloud to AI agent developersMore from Life Sciences
Nov 12 NHS England deletes claim that 137 hospital trusts benefit from Palantir's AI data platform Nov 12 Trial finds ChatGPT helped oncologists record more chemotherapy side effects, but patients did no better Nov 12 Lapsi Health adds emergency doctors' guidance to its Keikku clinical AI Nov 12 Unio Health Partners deploys Basata's AI agents for patient intake across 60 specialty clinics Nov 12 LERA Health launches women's health platform with an AI coach for $29 a monthFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Enza Capital secures $21 million for African AI fund
Nov 11, 2026
Funding
Flagship Pioneering Merges Three Biotech Platforms Into Etcelera
Oct 29, 2026
Healthcare
Pathos AI Raises $237 Million at $3 Billion Valuation
Oct 23, 2026
Funding
Biomatter Raises $18 Million for AI Enzyme Design
Nov 12, 2026
Funding
Isomorphic Labs Seeks $5 Billion at $50 Billion Valuation
Nov 05, 2026
Funding
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.